New Paper Published in "Stem Cells" Reporting In-Vivo Migration
Ability of Brainstorm Cell Therapeutics' NTF Cells
July 22, 2008
NEW YORK & PETACH TIKVAH, Israel--(BUSINESS WIRE)--BrainStorm Cell
Therapeutics Inc. (OTCBB:BCLI)
cell technologies and therapeutics, is pleased to announce that the
company's new therapeutic approach for treating neurodegenerative
disease was highlighted in a recent scientific paper that was
published in "Stem Cells" highlighting the company's patent
technology for treating neurodegenerative diseases. "Stem Cells" is
the most well known journal recording findings in the stem cell
field. The paper was authored by Tel Aviv University scientists.
The paper, reporting the recent work of Laboratory of Neurosciences,
FMRC, Department of Neurology, Rabin Medical Center, Sackler Faculty
of Medicine, Tel Aviv University, headed by BrainStorm's Chief
Consultants Prof. Eldad Melamed and Dr. Dani Offen, analyzes and
discusses rat NTF cells' ability to migrate in the brain from the
place of transplantation to damaged regions.
The NTF cells are generated from adult bone marrow derived stem
cells, and intended for autologous transplantation in Parkinson's
patients. The cells produce and secrete neurotrophic factors, which
are essential for the survival and outgrowth of neurons. The
production process of these cells, are Brainstorm's intellectual
property. This study shows that in a rat model of Huntington's
disease, a hereditary neurodegenerative disease, NTF cells that were
transplanted at a distance site, migrated towards the lesion at 19
days post grafting. This finding indicates the survival, integration
and migration abilities of NTF cells in the brain.
"The results of this study suggest that when our cells are
transplanted into the human brain, they may know where they are
needed, and may migrate to the damaged part of the brain, where they
will hopefully demonstrate their therapeutic capacity, and provide
trophic support for ill-functioning tissues. This recent study
provides additional support that we are on the right track,"
commented Dr. Dani Offen, BrainStorm's Chief scientific advisor.
About BrainStorm Cell Therapeutics Inc.
BrainStorm Cell Therapeutics Inc. is an emerging company developing
adult stem cell therapeutic products, derived from autologous (self)
bone marrow cells, for the treatment of neurodegenerative diseases.
The NurOwn(TM) patent pending technology is based on discoveries made
by the scientific team led by prominent neurologist Professor Eldad
Melamed, Head of Neurology at Rabin Medical Center, and expert cell
biologist Dr. Daniel Offen, Head of the Neuroscience Laboratory at
the Felsenstein Medical Research Center of Tel-Aviv University. The
technology allows for the differentiation of bone marrow-derived stem
cells into functional neurons and astrocytes, as demonstrated in
animal models. The Company holds rights to develop and commercialize
the technology through an exclusive, worldwide licensing agreement
with Ramot at Tel Aviv University Ltd., the technology transfer
company of Tel-Aviv University. The Company's initial focus is on
Parkinson ALS and Spinal Cord Injury, although its technology has
promise for treating several other diseases including MS,
Huntington's disease and stroke.
Safe Harbor Statement
Statements in this announcement other than historical data and
information constitute "forward-looking statements" and involve risks
and uncertainties that could cause BrainStorm Cell Therapeutics
Inc.'s actual results to differ materially from those stated or
implied by such forward-looking statements, including BrainStorm's
ability to complete its equity financing transactions previously
disclosed. The potential risks and uncertainties include, among
others, risks associated with BrainStorm Cell Therapeutics Inc.'s
limited operating history, history of losses and expectation to incur
losses for the foreseeable future; dependence on its license to
Ramot's technology; ability, together with its licensor, to
adequately protect the NurOwn(tm) technology; dependence on key
executives and on its scientific consultants; ability to identify,
negotiate and successfully implement strategic partnering
relationships; ability to complete clinical trials successfully and
to obtain required regulatory approvals; competition with companies,
some of which have greater resources and experience in developing and
obtaining regulatory approval for treatments in BrainStorm Cell
Therapeutics Inc.'s market; the limited public trading market for
BrainStorm Cell Therapeutics Inc.'s stock which may never develop
into an active market; and other factors detailed in BrainStorm Cell
Therapeutics Inc.'s annual report on Form 10-KSB, quarterly reports
on Form 10-QSB, current reports on Form 8-K and other filings with
the Securities and Exchange Commission available at
http://www.sec.
not undertake any obligation to update forward-looking statements
made by us.
Contacts
BrainStorm Cell Therapeutics Inc.
Chaim Levinson, +972-545-633683
Clevinson@brainstor
http://www.business
ndmViewId=news_
«¤»¥«¤»§«¤»¥«¤»§«¤»¥«¤»«¤»¥«¤»§«¤»¥«¤»§«¤»¥«
¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯
StemCells subscribers may also be interested in these sites:
Children's Neurobiological Solutions
http://www.CNSfoundation.org/
Cord Blood Registry
http://www.CordBlood.com/at.cgi?a=150123
The CNS Healing Group
http://groups.yahoo.com/group/CNS_Healing
____________________________________________
«¤»¥«¤»§«¤»¥«¤»§«¤»¥«¤»«¤»¥«¤»§«¤»¥«¤»§«¤»¥«
¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯
Yahoo! Groups users, check out this limited time offer from Blockbuster! Rent DVDs free for a month!
Change settings via the Web (Yahoo! ID required)
Change settings via email: Switch delivery to Daily Digest | Switch format to Traditional
Visit Your Group | Yahoo! Groups Terms of Use | Unsubscribe
__,_._,___
No comments:
Post a Comment